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Abstract: The levonorgestrel-releasing intrauterine system (LNG-IUS) is a safe, effective 
and acceptable form of contraception used by over 150 million women worldwide. It also has 
a variety of noncontraceptive benefits including treatment for menorrhagia, endometriosis, 
and endometrial hyperplasia. The LNG-IUS has also been used in combination with estrogen 
for hormone replacement therapy and as an alternative to hysterectomy. Overall, the system 
is very well tolerated and patient satisfaction is quite high when proper education regarding 
possible side effects is provided. However, despite all of the obvious benefits of the LNG-IUS, 
utilization rates remain quite low in the developed countries, especially in the United States. 
This is thought to be largely secondary to the persistent negative impressions from the Dalkon 
Shield intrauterine experience in the 1970s. This history continues to negatively influence the 
opinions of both patients and health care providers with regards to intrauterine devices. Providers 
should resolve to educate themselves and their patients on the current indications and uses for 
this device, as it, and intrauterine contraception in general, remains a largely underutilized 
approach to a variety of women’s health issues.
Keywords: Mirena®, levonorgestrel-releasing, intrauterine system, intrauterine contraceptive 
device
Introduction
Worldwide, intrauterine devices (IUDs) are the most widely used and effective reversible 
contraceptive method and are safe, extremely “low maintenance” contraceptives. They 
are second only to female sterilization as the most prevalent method of family planning 
worldwide (13.6% vs 20.5%).1 Over 150 million women worldwide use the IUD for 
contraception. However, for a variety of reasons, including the continued concern 
many women have about the morbidity and mortality associated with IUDs resulting 
(whether they know it or not) from the Dalkon shield experience of the 1970s, there 
is a large disparity between the numbers of users in developing versus developed 
countries. There is an especially low utilization rate within the United States. Nearly 
15% of women who use contraception in less developed countries choose the IUD, 
compared with only 8% of women in developed countries and only 2% in the United 
States. Two thirds of worldwide IUD use (over 100 million women) is represented 
by China alone.2
There is currently a wide variety of IUDs available worldwide; some are inert, some 
are copper containing, and some are medicated with levonorgestrel or indomethacin. 
They also come in a wide variety of sizes and shapes including T-shaped and 
“frameless” devices. This article will focus specifically on the LNG-IUS, exploring Therapeutics and Clinical Risk Management 2009:5 562
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mechanism of action, safety, efficacy, variety of uses, and 
patient acceptability.
Mechanism of action  
of the levonorgestrel-releasing 
intrauterine system
The levonorgestrel-releasing intrauterine system (LNG-
IUS) has been available in Europe since 1990 and the 
United States since 2000. It is marketed under the name 
Mirena® (Bayer Schering Pharma, Berlin, Germany). The 
LNG-IUS provides highly effective contraception for up 
to five years, with potential for approval for up to seven 
years in the near future. The mechanisms of action of the 
LNG-IUS are similar to that of levonorgestrel implants or 
levonorgestrel-containing mini-pills, although it accom-
plishes these effects with much lower peak serum levels than 
other progestin-containing contraceptives (0.1–0.4 ng/ml 
vs 1.7–15.2 ng/ml with combined and progestin-only oral 
contraceptives, respectively, and 5.4 ng/ml for combined 
vaginal preparations).1 The LNG-IUS is a T-shaped device 
composed of a cylinder containing 52 mg of LNG covered 
by a rate-controlling membrane which serves to regulate 
the rate of hormonal release (Figure 1).3 Initially, 20 µg of 
levonorgestrel is released every 24 hours from this polymer 
cylinder. This decreases to 11 µg every 24 hours by the end of 
five years, with an average release rate of 14 µg per day over 
the life of the IUS. Levonorgestrel, a highly potent second 
generation progestin, thickens cervical mucus and suppresses 
endometrial proliferation (preventing decidualization of 
the stroma). This creates a hostile environment for sperm 
survival, inhibiting motility and capacitation with the net 
effect combining to prevent fertilization.1
The LNG-IUS also produces endometrial thinning with 
fragile superficial vessels which, in the unlikely event of 
fertilization, may prevent implantation. The low serum levels 
of absorbed progestin are below the threshold for inhibition 
of ovulation, so that most women with the LNG-IUS continue 
to ovulate regularly.1
As a result of these various contraceptive actions, the 
efficacy rate of the LNG-IUS is high, with only 0.1% of 
women experiencing an unintended pregnancy within the 
first year of typical use. In four clinical studies, representing 
more than 10,000 woman-years of use, the average Pearl 
Index (a statistical estimation of the number of unintended 
pregnancies in 100 woman-years of exposure to a contracep-
tive method) was 0.1.4
Candidates and contraindications 
for intrauterine contraception  
and the LNG-IUS
Candidates and contraindications  
for intrauterine devices in general
Intrauterine contraceptive devices are appropriate contra-
ceptive options for women who desire a very convenient, 
long-term contraceptive or who are considering sterilization. 
While there are contraindications to utilization of an IUD, 
they are relatively few compared to some other methods. 
Some contraindications, for example pregnancy, are absolute 
and undisputed. However, other contraindications, such as 
patients at increased risk of sexually transmitted infections or 
nulliparous women, are more controversial. The recommen-
dations regarding these issues vary based on which specific 
organization is consulted (Table 1).
One of the most contentious contraindications to 
IUD use relates to patients who are perceived to be at 
increased risk for sexually transmitted infections (STIs). 
This concern likely dates back to the experience with 
the Dalkon Shield in the 1970s. The Dalkon Shield IUD 
was associated with an unacceptably high risk of pelvic 
inflammatory disease, tubal infertility and septic abortion, 
to a significant extent secondary to its braided polyfilament 
tail.5 It was subsequently removed from the market, and is 
thought by many to be responsible for the initial significant 
decline and continued slow increase in numbers of patients 
interested in using IUDs for contraception. After the 
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Table 1 Contraindications to the levonorgestrel-releasing intrauterine system according to organizational recommendations
Condition ACOG55 WHO13,16  
(for the definition of risk 
categories see Appendix B)
Manufacturer3
Uterine anomaly 
(including fibroids causing 
distortion of the uterine 
cavity)
Contraindicated Risk category 4 Contraindicated
History of pelvic 
inflammatory disease
Contraindicated  
(past three months only)
No contraindication Contraindicated  
(if no subsequent 
pregnancy)
Post-partum endometritis 
or septic abortion in the 
last three months
Contraindicated immediate insertion only, risk 
category not defined
Contraindicated
Active cervicitis/vaginitis Contraindicated initiation of LNG-iUS is risk 
category 4, continuation is risk 
category 2 for cervicitis; both 
are risk category 2 for vaginitis
Contraindicated
immunosuppression  
(eg, leukemia, AiDS, 
intravenous drug abuse)
No recommendation initiation is risk category 3, 
continuation category 2. 
if AiDS patient is clinically 
well on antiretroviral therapy, 
initiation is also category 2. 
Not contraindicated in Hiv.
Contraindicated
Known or suspected 
cervical dysplasia/genital 
bleeding of unknown 
etiology
Contraindicated initiation is risk category 4, 
continuation is risk category 2
Contraindicated
Known or suspected 
breast carcinoma
Contraindicated Risk category 4 for current, 
category 2 for past with no 
evidence of disease for the last 
five years
Contraindicated
Pregnancy Contraindicated Risk category 4 Contraindicated
Post-partum 48 hours 
(including insertion 
immediately after 
delivery of the placenta)
No recommendation Risk category 1 if not breast 
feeding, category 3 if breast 
feeding
No recommendation
Post-partum 48 hours 
to 4 weeks
No recommendation Risk category 3 No recommendation
Active viral hepatitis, 
liver tumor (benign or 
malignant), cirrhosis
Not recommended for 
“current liver disease”
Risk category 3 for 
malignant hepatoma, benign 
hepatocellular adenoma, or 
decompensated cirrhosis, 
category 2 for focal nodular 
hyperplasia
Contraindicated
History of, or condition 
that predisposes to, 
ectopic pregnancy
No contraindication No contraindication Recommends 
caution
Current DvT/Pe No recommendation Risk category 3, category 2 if 
established on anticoagulant 
therapy
No recommendation
Abbreviations: ACOG,   American College of Obstetricians and Gynecologists;   AIDS, acquired immunodeficiency syndrome; DVT, deep vein thrombosis; HIV, human 
immunodeficiency virus; PE, pulmonary embolism;   WHO,   World Health Organization.
dismal experience with the Dalkon Shield physicians 
understandably were, and despite current reassuring 
data often continue to be, hesitant to prescribe this for 
unmarried women or patients with multiple sexual partners 
because of the persistent concern over serious pelvic 
infections and implications for future fertility. However, 
numerous studies on the currently available versions of 
the IUD have shown that, overall, IUD users are no more Therapeutics and Clinical Risk Management 2009:5 564
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likely to suffer from PID than control women. One model 
estimated that the risk of clinical PID secondary to IUD use 
is only 0.15%.6 Another recent study evaluating a high-risk 
population in West Africa showed the risk of PID related 
to IUD insertion to be only 0.075%.7 One randomized 
trial (with data collection in the early 1980s) showed a 
decreased rate of PID among LNG-IUS users compared 
to users of a copper-containing IUD.8 The IUD may, 
therefore, be a reasonable option for women who may be at 
risk for sexually transmitted infections. This is especially 
the case where prevalence in the community as a whole 
may be high but individual risk may be low (ie, no current 
or recent history of an STI or the patient uses condoms 
regularly if she has more than one partner). Morrison 
and colleagues developed a checklist to help with risk 
assessment for STIs in candidates for IUD insertion which 
may be helpful with management decisions (Appendix A).9 
Of note, all women must still be counseled on safe sex 
practices, and condom use must be encouraged.
The appropriateness of IUD use in nulliparous women 
has also been controversial because of a variety of concerns 
specific to this group. First, because of the smaller size of 
the uterus it was thought that there might be an increased 
expulsion rate. In addition, because of the more stenotic 
nulliparous os, the device may cause increased pain with 
insertion. There has also been concern over a possible 
increased rate of infertility in these women, again secondary 
to the concern over increased rates of PID with the IUD and 
the thought that nulliparous women are less likely to be in 
stable, monogamous relationships. However, these concerns 
are not supported by recent studies. A retrospective cohort 
study of 129 nulliparous and 332 parous women showed that 
rates of expulsion for the levonorgestrel-releasing IUDs were 
0% to 0.2% per year, and that nulliparous women did not show 
more complications than parous women.10 A comparative 
cross-sectional study of 227 nulliparous women and 2,080 
parous women showed similar reasons for removal between 
the two groups: 49.1% vs 48.2% because of device expiration, 
21.7% vs 15.4% desired planned pregnancy, 4.8% vs 6.3% 
were secondary to accidental pregnancy, 1.6% vs 1.1% because 
of PID. There were actually decreased rates of expulsion in 
the nulliparous group (1.6% vs 5.1%), and slightly increased 
rates of pain/bleeding (14.5% vs 10.2%).11 According to the 
medical eligibility criteria for contraceptive use developed 
by the World Health Organization (WHO), nulliparity is 
a condition for which the advantages of using intrauterine 
contraception generally outweigh the theoretical or proven 
risks (risk category 2. For the full definition of  WHO risk 
categories please see Appendix B).12 The intrauterine device 
is, therefore, generally considered to be a safe and effective 
contraceptive which should be offered to nulliparous women 
as part of their family planning counseling.
There are no WHO restrictions for using IUDs among 
women who have uncomplicated valvular disease. When 
valvular heart disease is complicated by pulmonary hyper-
tension, atrial fibrillation, or subacute bacterial endocarditis, 
prophylactic antibiotics should be administered to women 
with these conditions before an IUD is inserted to prevent 
endocarditis.
Candidates and contraindications  
for the LNG-iUS
The WHO provides highly useful guidelines regarding the 
appropriateness of the LNG-IUS for women with a variety 
of medical conditions (see Appendix B for the definition of 
WHO risk categories for eligibility for use of an intrauter-
ine device). According to the WHO, women who have any 
degree of hypertension can use a LNG-IUS if no other risk 
factors for cardiovascular disease are present. When multiple 
risk factors do exist, the risk of cardiovascular disease may 
increase substantially. For this reason, because progestins 
have been shown in clinical trials to influence lipid metabo-
lism,13 there has been concern, albeit theoretical, about the 
effect of levonorgestrel-releasing IUDs on lipid levels in 
women with a history of heart disease or stroke.12 However, 
these concerns about the effect of the LNG-IUS on lipid pro-
files have not been borne out. A recent study of 48 patients 
who had the LNG-IUS inserted for menorrhagia showed no 
significant change from baseline in mean total cholesterol, 
triglycerides, low-density lipoprotein (LDL) or very low 
density lipoprotein (VLDL) at the end of one year.14 Another 
study of 92 women with the LNG-IUS inserted for menor-
rhagia showed a marginally significant reduction in total 
cholesterol from baseline, a reduction in HDL at 6 months 
which reverted to baseline by one year, while triglycerides, 
LDL, apolipoprotien A1 and apolipoprotein B remained 
stable over the course of 18 months.15 Therefore, though the 
WHO recommendations warn of a theoretical effect of the 
LNG-IUS on lipid levels and caution its use in women with 
multiple cardiac risk factors, studies do not show this to be 
a significant problem associated with the LNG-IUS.
Progestins are thought to increase the risk for deep vein 
thromboses (DVTs) and pulmonary emboli, although this 
increase is substantially less with a levonorgestrel-releasing 
IUS than with combined oral contraceptives. Since risks 
associated with the LNG-IUS are even greater for women Therapeutics and Clinical Risk Management 2009:5 565
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who have a current DVT, the WHO states that the risks of 
using the LNG-IUS in such a situation usually outweigh 
the benefits (risk category 3) until they are established on 
anticoagulant therapy (risk category 2).12,16
Among women who are infected with the human 
immunodeficiency virus (HIV) or are at risk of becoming 
infected with this pathogen, there is no known interaction 
between antiretroviral therapy and LNG-IUS use. The WHO, 
however, classifies insertion of a LNG-IUS in a woman 
with acquired immunodeficiency syndrome (AIDS) as a 
category 3 risk and continuation of the IUD as a category 2 
risk unless the patient is clinically well and on antiretroviral 
therapy. In this case, insertion of an IUS is then considered 
to provide benefits that generally outweigh any theoretical 
or proven risk. Although IUD use is not associated with an 
increased risk of HIV transmission to sexual partners, these 
women should be counseled about safe sex practices and 
condom use must be encouraged.12
Insertion of the LNG-IUS
Although the intrauterine contraceptive device should ideally 
be inserted within the first seven days following a woman’s 
menstrual cycle, it can be inserted at any time during the cycle 
if it is reasonably certain that she is not pregnant and has not 
been at risk of pregnancy during that cycle. As discussed in 
more detail later (please see “Efficacy of the LNG-IUS”), 
an IUD may be safely inserted immediately after uncom-
plicated spontaneous or induced abortions, including those 
that are performed during the second trimester. Expulsion, 
pregnancy, and removal rates after first-trimester termination 
are comparable to those found in studies in which the device 
was inserted during or immediately after menses. The shorter 
the period of gestation at the time of spontaneous or induced 
abortion, the lower the event rates following IUD insertion. 
The LNG-IUS can also be safely inserted immediately after 
childbirth, but there are associated risks with insertion during 
the immediate postpartum period. If an IUD is inserted within 
the first 48 hours after childbirth, the risk of expulsion is 
greater than interval insertion, although the risk of expulsion 
is somewhat lower if the IUD is inserted within 10 minutes 
of the delivery of the placenta. If an IUD is inserted 48 hours 
and up to four weeks after childbirth, the risk of perforation 
is greater. According to the WHO medical eligibility criteria 
for contraceptive use, there are no restrictions for inserting 
an IUD four or more weeks after childbirth; however, no 
distinction is made between a vaginal or caesarean delivery. 
The type of delivery is important, because a cesarean section 
can distort the uterine anatomy. If the distortion is found to 
be significant during a bimanual examination, then inserting 
the IUD may be aided by uterine ultrasonography.17
Adhering to the proper insertion method and using a 
sterile or “no-touch” technique are sufficient to decrease the 
risk of infection, uterine perforation, and expulsion. Data 
indicate that antibiotic prophylaxis does not prevent the rare 
occurrence of infections acquired at the time of insertion. 
A Cochrane review performed to assess the effectiveness of 
prophylactic antibiotic administration before IUD insertion 
in reducing IUD-related complications and discontinuations 
within three months of insertion showed little benefit from 
prophylactic antibiotics on early removal or occurrence of 
PID following insertion.18 Prophylactic antibiotics are there-
fore not recommended prior to insertion of the IUD.
Pain may occur during the insertion procedure that 
may result from a vasovagal reaction, the need for cervical 
dilation, difficulty with insertion, and uterine perforation. 
While some clinicians administer ibuprofen or another non-
steroidal anti-inflammatory drug (NSAID) to control such 
pain, a recent study of 2,019 first-time IUD users found that 
ibuprofen had no significant impact on reducing pain.19 In a 
comparative study conducted in the United Kingdom, 102 
women presenting for IUD insertion were randomly assigned 
to 1 of 3 groups: no pretreatment, pretreatment with 2% 
lignocaine gel (Instillagel) applied to the cervical canal, and 
pretreatment with an inert gel. Pain scores for women in the 
nontreatment groups were significantly higher (p  0.025) 
than those in the lignocaine group. These results suggest 
that a local lignocaine gel has the potential for reducing the 
pain and discomfort experienced during IUD insertion.20 In 
an attempt to reduce cervical resistance, a randomized, con-
trolled trial was undertaken among 80 nulliparous women 
randomly assigned to receive sublingually 400 µg misopro-
stol and 100 mg diclofenac or 100 mg diclofenac alone one 
hour prior to IUD insertion. Following treatment with miso-
prostol, insertion was significantly easier with fewer difficult 
and failed attempts at insertions than in the control group. 
However, pain scores, estimated using a visual analogue 
scale (VAS; 1–10), were not different between the groups.21 
Therefore, there may be some benefit to use of misoprostol 
for cervical ripening prior to LNG-IUS insertion as well as 
local anesthetic use for pain control, while NSAIDs appear 
to be of little benefit.
Efficacy of the levonorgestrel-
releasing IUS
The IUD, in general, is one of the most effective forms of 
contraception available today, with a global cumulative Therapeutics and Clinical Risk Management 2009:5 566
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pregnancy rate of 2% at five years. The LNG-IUS, in 
particular, is possibly the most effective IUD available 
according to numerous studies that show its global cumulative 
pregnancy rate to be 0.5%.22 A large randomized-controlled 
trial of 2,244 women over seven years showed a pregnancy 
rate of 1.1% with the LNG-IUS compared with 1.4% with 
the TCu380.23 In two other seven-year follow up studies with 
293 and 82 women respectively, there were no pregnancies in 
women using the LNG-IUS.24,25A Cochrane review in 2004 
showed the LNG-IUS to be as effective as copper IUDs with 
a copper surface area of 250 mm2, and more effective than 
those with 250 mm.22,26
The LNG-IUS is also an effective option for women to 
choose immediately post abortion. Multiple studies have 
shown that copper-releasing IUDs are safe and effective 
during this timeframe. Fewer studies have been done look-
ing specifically at the LNG-IUS under this circumstance; 
however, they have shown it to be at least as effective as the 
copper IUD. One study followed 305 women who received 
the Mirena® IUS immediately post-abortion for up to five 
years. There were a total of two pregnancies for a pregnancy 
rate of 0.8% at five years. There was a discontinuation rate 
secondary to expulsion of 7.1% at one year and 10.5% at five 
years27 which is obviously higher than the interval expulsion 
rate of 2%–3% per year,28 but not significantly different 
than that of the NovaT (8.6% at one year and 15.4% at five 
years).28 A LNG-IUS may, therefore, be safely inserted 
immediately after either uncomplicated spontaneous or 
induced abortions.
The levonorgestrel-releasing intrauterine system can also 
be safely inserted immediately after childbirth, but there is 
also an increased risk of expulsion compared with interval 
insertion. A study of 19 women who received a post placental 
LNG-IUS, defined as placement within 10 minutes of pla-
cental delivery, showed an expulsion rate of 10.5% and no 
infections.27 There are no studies that specifically examine 
the timing of LNG-IUS insertion post partum, but one done 
with a copper-releasing IUD showed post-placental IUD 
insertion to have significantly lower expulsion rate (14.3% 
complete and 22.6% partial) than early post partum insertion, 
defined as taking place 10 min to 72 hours after delivery of 
the placenta, at the end of one year (18.6% complete and 
51.2% partial). Both rates were much higher than interval 
insertion (3.8% complete and 3.1% partial). There were no 
perforations in either of the post partum groups, and 2.3% 
perforation rate in the interval groups.29 Insertion of the LNG-
IUS is therefore a reasonable, almost effortless, option for 
post placental insertion if the woman is properly counseled 
about the increased risk of expulsion versus interval insertion 
and receives proper counseling on checking the IUS strings 
and receives appropriate clinical follow-up. For many low-
resource settings, since the cervix (or uterus in the case of 
insertions at Cesarean delivery) is open at delivery and the 
patient is commonly in lithotomy position, post-placental 
insertion may reduce the barriers to interval insertions such as 
lack of speculae, tenacula, sounds, exam tables, and already 
crowded clinics.
Noncontraceptive benefits  
of LNG-IUS
Like oral contraceptives, the levonorgestrel-releasing 
intrauterine system confers important noncontraceptive health 
benefits. The Mirena® LNG-IUS can be effective in treating 
a variety of gynecological disorders including menorrhagia, 
dysmenorrhea, pain associated with endometriosis, anemia, 
endometrial hyperplasia and can be used as an alternative to 
hysterectomy for women with bleeding problems as well as 
an adjunct to estrogen replacement therapy.
The LNG-IUS as treatment  
for menorrhagia
Menorrhagia, defined as 80 mL of menstrual blood loss, is 
a common health problem affecting up to 2.5 million women 
in the United States annually. It accounts for a loss of 8% 
of employee wages in the USA, and is a major reason for 
women to present to their health care provider for invasive 
procedures, including hysterectomy.30 The prevalence of 
menorrhagia increases with increasing age, peaking in 
the perimenopausal period. Nearly half a million women 
annually in the United States alone undergo hysterectomy 
because of bleeding disorders, with the associated health 
care costs, time from work, and morbidity that accompany 
this operative treatment.30 There are a variety of medical 
and surgical treatments available for menorrhagia, includ-
ing prostaglandin synthetase inhibitors, antifibrinolytic 
agents, oral contraceptive pills, and endometrial ablation. 
However, most of these treatments have only been shown to 
improve menstrual bleeding by 20%–50%.30 In addition, the 
associated side effects and repetitive nature of these treat-
ments significantly impairs patient compliance. In contrast, 
the LNG-IUS has been used in numerous studies as a treat-
ment of menorrhagia, with a reduction in menstrual blood 
flow of 86%–97%.30 One study comparing the LNG-IUS 
and norethisterone showed that the LNG-IUS reduced 
menstrual blood flow by 94%, with norethisterone by a close 
87%. However, after three cycles of treatment, 76% of the Therapeutics and Clinical Risk Management 2009:5 567
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LNG-IUS group wished to continue the treatment, compared 
with only 22% of the medical therapy group.31
In addition, the LNG-IUS has been used in numerous 
studies to compare outcomes with hysterectomy for treat-
ment of menorrhagia. A randomized controlled trial of 
236 women assigned either to LNG-IUS or hysterectomy 
showed that after one year the two treatments were associ-
ated with equal improvements in health status, quality of life, 
and psychosocial well-being, but the IUS was more cost-
effective. Of note, 20% of the women in the LNG-IUS group 
did go on to receive hysterectomies because of continued 
bleeding.32 Another study which looked specifically at the 
cost-effectiveness of oral contraceptives versus LNG-IUS 
versus surgical management (including both ablation and 
hysterectomy) for dysfunctional uterine bleeding (DUB) 
showed the LNG-IUS to be the most cost-effective of all three 
treatments.33 A Cochrane review of the subject concluded 
that use of the LNG-IUS results in a significant decrease 
from baseline in the amount of menstrual bleeding, and that 
it is more cost-effective as a treatment for menorrhagia than 
hysterectomy both at one and five years.34 The LNG-IUS is, 
therefore, a satisfactory, effective, and economical alternative 
to medical and surgical treatment of menorrhagia.
The LNG-IUS as treatment  
for endometriosis
Endometriosis is a significant problem affecting 5%–10% of 
reproductive age women in the United States.35 It is associ-
ated with chronic pelvic pain, dyspareunia and infertility, and 
is often a significant detriment to a patient’s quality of life. 
Treatment has historically consisted of some combination of 
nonsteroidal anti-inflammatory medications (NSAIDs), pro-
gestational medications such as depot medroxyprogesterone 
acetate (DMPA) that function as anti-estrogens, ovulation 
suppression with oral contraceptive pills, androgenic medi-
cations such as danazol, gonadotropin-releasing hormone 
(GnRH) analogues to induce temporary pseudo-menopause, 
and surgical ablation. However, the hypoestrogenic side 
effects associated with many of these medical treatments 
and the invasive nature of the surgical treatment are a limit-
ing factor to both the clinical ability to continue the treat-
ment long term and patient compliance. The LNG-IUS has 
recently been studied as an alternative for treating the pain 
and symptoms associated with endometriosis, as it addresses 
both the patient compliance and the long-term use issues. 
A randomized-controlled clinical trial of 82 women with 
chronic pelvic pain from endometriosis compared 39 women 
treated with the LNG-IUS with 43 women treated with a 
GnRH analogue. After six months, both groups showed 
significant improvement in pain scores throughout the six 
months of treatment, with those women with stage III or IV 
endometriosis receiving the fastest improvement. There was 
no difference in quality of life reported, and the LNG-IUS 
group had the benefits of fewer hypoestrogenic side effects, 
and only requiring one intervention every five years.36 After 
36 months, 59% (n = 23) of the women in the LNG-IUS group 
were still using the device. The VAS pain score in this group 
was 0–3 (indicating excellent pain control) in 82.6%, and 7 
in only 8.6%. In the former users of the GnRH analogue, 28% 
were using some form of hormonal contraceptives to control 
pain, and 47.5% continued to have excellent pain control, 
while only 2.5% had a pain score 7. Therefore, while both 
treatments are effective in pain control for up to 3 years, the 
LNG-IUS may be the treatment of choice for women who 
do not wish to become pregnant because it can provide both 
effective pain control and contraceptive protection.37
Another study of 34 women with surgically staged 
minimal to moderate endometriosis who were treated with 
the LNG-IUS for up to 36 months showed a decrease in the 
visual analog pain scale (VAS) from an initial score of 7.7/10 
to 2.7 at 36 months. There was also a decrease in the verbal 
rating scale (VRS) of both dysmenorrhea and noncyclic 
pelvic pain from an initial 25/96 to 8.4 after 36 months as 
well as a decrease in total days of pain per 28-day period 
from 15.0 to 6.0 after 12 months.38
A randomized-controlled clinical trial of 40 women who 
underwent conservative surgical treatment for moderate to 
severe endometriosis compared 20 women who received a 
postoperative LNG-IUS with 20 women who were managed 
expectantly postoperatively. The study showed that 10% of 
the women who received the LNG-IUS had a recurrence of 
moderate to severe endometriosis after 12 months, compared 
with 45% of the expectantly managed group. There was also 
an absolute risk reduction in recurrence of dysmenorrhea 
in the LNG-IUS group of 35%, as well as a decrease in 
recurrence rates of dyspareunia.39 The LNG-IUS appears to 
be an effective treatment for the pain symptoms associated 
with endometriosis, and is associated with fewer interven-
tion requirements, fewer hypoestrogenic side effects, and 
increased patient satisfaction rates than many of the other 
alternative treatments clinically available.
The LNG-IUS as treatment  
for adenomyosis
Adenomyosis is a relatively common disorder affecting 
women, usually in their 40s and 50s, characterized by the Therapeutics and Clinical Risk Management 2009:5 568
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presence of heterotopic endometrial glands and stroma in 
the myometrium with hyperplasia of the adjacent smooth 
muscle. The symptoms include menorrhagia (40%–50%), 
dysmenorrhea (15%–30%), and metrorrhagia (10%–12%).40 
Historically, diagnosis and definitive treatment for 
adenomyosis has been hysterectomy. However, diagnosis 
has recently become possible using a combination of 
transvaginal ultrasound and magnetic resonance imaging. 
As a result, there has been a concerted effort on the part of 
gynecologists to find an effective, but less invasive treat-
ment for the disorder. The options for this condition include 
endometrial ablation, danazol and GnRH agonists. However, 
endometrial ablation is not effective for this condition as it 
does not penetrate deeply enough into the myometrium. In 
addition, as discussed previously with regards to treatment for 
endometriosis, in light of the side effects of the other forms 
of medical treatment listed, the LNG-IUS is becoming an 
increasingly attractive option for treatment of adenomyosis. 
It is hypothesized to work on adenomyosis in two ways. First, 
as discussed earlier, it causes decidualization and atrophy 
of the endometrium, therefore decreasing the amount of 
menstrual flow. Secondly, the levonorgestrel down regulates 
estrogen receptors in glandular and stromal endometrial tis-
sues. This likely prevents further estrogen stimulation of the 
adenomyosis foci within the myometrium, causing them to 
atrophy and shrink. This may lead to decreased menstrual 
flow by allowing the myometrium to better contract, limit-
ing the blood loss during menses, and also accounts for the 
decreased size of the uterus noted.41
Several studies have been performed to evaluate the 
effectiveness of the LNG-IUS as a treatment for adenomosis. In 
one small study of 25 women with menorrhagia associated with 
adenomyosis, the subjects were treated with the LNG-IUS and 
followed for up to 12 months. The average pictorial blood loss 
decreased by approximately 75% (211 ± 61 to 44 ± 18 mL). 
In addition, both uterine volume and endometrial thickness 
decreased significantly, while there was a significant increase 
in hemoglobin, serum iron and ferritin levels.39
Another study was performed on 47 women with adeno-
myosis. Each received a LNG-IUS and were followed for up 
to 36 months. At the end of 36 months 32 women were still 
enrolled in the study. In these women, serum hemoglobin 
and ferritin levels increased significantly and CA-125 values 
significantly decreased. In addition, uterine volume decreased 
from 156.85 ± 49.79 to118.64 ± 41.35 mL at 12 months. 
However, uterine volume increased from 24 to 36 months, 
to 139.87 ± 29.93 mL. At 36 months, this difference was not 
significantly different from the initial pretreatment volume. 
Pain scores decreased significantly from 8.55 ± 1.02 to 
1.93 ± 0.95 by 6 months and remained there at 24 months. 
Menstrual blood flow was also markedly reduced, with a 
reduction of 90%, and remained similar at 24 months. 
However, as with uterine size, the pain scores and blood 
flow increased again after 36 months, though they were still 
significantly less than the initial values. Though the exact 
cause for this phenomenon is unknown, it is hypothesized 
that it could be attributed to the decreased amount of hormone 
released by the LNG-IUS daily over time.42 Regardless, 
the LNG-IUS does appear to be an effective treatment for 
adenomyosis with improvement in pain and bleeding scores 
over two years. Further studies will need to address whether 
replacing the LNG-IUS after 2–3 years will keep the pain and 
bleeding scores from increasing again over time.
The LNG-IUS as treatment  
for endometrial hyperplasia
Endometrial hyperplasia is classified according to increas-
ingly abnormal architectural and cytologic criteria as simple, 
complex, and atypical hyperplasia. Cytologic atypia is the 
most important prognostic factor with regard to progres-
sion to endometrial cancer. For nonatypical hyperplasia, 
there is a 1%–3% chance of progression to cancer, with 
a 72% chance of regression after expectant management. 
In contrast, for atypical hyperplasia there is an 8%–30% 
chance of progression to endometrial carcinoma, with only 
a 54% chance of spontaneous regression with expectant 
management.43 In addition, endometrial cancer can coexist 
with atypical hyperplasia in up to 25% of cases.44 Because 
of the high potential for progression of atypical endome-
trial hyperplasia to carcinoma hysterectomy is generally 
considered to be the standard of care unless the patient 
desires to retain potential fertility or there are medical 
contraindications to surgery. In contrast, because nonatypi-
cal hyperplasia is generally considered to be low risk for 
progression to cancer, many patients and providers consider 
hysterectomy too invasive a treatment. Though there is no 
consensus on the best way to treat these women, they have 
often been treated with oral progestins. However, because of 
the systemic nature of the treatment there can be significant 
side effects that limit compliance with treatment, and when 
the treatment is discontinued the hyperplasia can recur. As 
a result, numerous studies have been done to evaluate the 
LNG-IUS as an alternative therapy to hysterectomy for those 
with endometrial hyperplasia without atypia. One study of 
12 women diagnosed with hyperplasia without atypia and 
eight women with atypia was performed to evaluate the Therapeutics and Clinical Risk Management 2009:5 569
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long-term (three-year) remission rate after treatment with 
a LNG-IUS. Nineteen of the twenty women in this study 
developed a normal endometrium, with the other woman 
continuing to have focal atypical hyperplasia with a normal 
endometrial stripe at the end of 36 months. In addition, at the 
beginning of the study all women with atypical hyperplasia 
showed progesterone receptor expression in the epithelial 
cells. This expression declined significantly over the course 
of the study, marking the strong antiproliferative effect of 
the LNG-IUS, with its inhibition of estrogen bioactivity and 
suppression of the endometrium.45
A larger study was done involving long term (up to 
106 months) follow up of 258 women with endometrial 
hyperplasia. Of these 258 women, 85 women were treated 
with 10 mg oral medroxyprogesterone acetate (MPA) for 
10 days per cycle for three to six months, 66 women had 
a LNG-IUS placed for 3–108 months, and 107 women 
underwent control biopsy alone with observation. After six 
months 100% of the LNG-IUS group responded, compared 
with 54% of the oral MPA group, while 50% of the observa-
tion group spontaneously regressed. After 58–106 months, 
44 of the women still retained their LNG-IUS, and 100% of 
these women responded, compared with 63% of the women 
who had their LNG-IUS removed, 60% of the oral MPA 
group and 49% of the observation only group. There was 
no significant difference between these last three groups.46 
Though larger studies with long term follow up need to be 
done for more definitive evidence, the studies so far do seem 
to indicate that the LNG-IUS is a superior treatment modality 
for endometrial hyperplasia than low dose oral progestins or 
observation alone.
The LNG-IUS as adjunct  
to estrogen replacement therapy
It is clear that in peri- and postmenopausal females who 
retain their uteri and desire estrogen replacement therapy 
secondary to climacteric side effects it is essential to provide 
progestin medication in order to counteract the proliferative 
effect of estrogen on the endometrium. The standard treat-
ment has been to use a cyclic oral progestin preparation 
at the end of each cycle in combination with the estrogen. 
However, the oral regimen is associated with cyclic vaginal 
bleeding which is burdensome to some, and can also have 
a variety of androgenic side effects. In addition, multiple 
studies have shown possible links with systemic progesterone 
and increased cardiovascular risks in addition to increased 
breast cancer risks.47,48 The LNG-IUS has been studied as 
an alternative method of providing locally acting progestin 
which can accomplish the endometrial protective effects 
with a minimal amount of adverse side effects secondary to 
its significantly decreased serum concentration. One study 
of 40 perimenopausal women complaining of climacteric 
symptoms evaluated two treatment regimens: three week 
cyclic treatments with 2 mg oral estradiol (E2) valerate 
combined with 250 µg of oral levonorgestrel for the last 
10 days of each cycle versus 2 mg of E2 valerate continuously 
with the LNG-IUS. After one year the subjective symptoms 
in both groups were improved, and none of the women had 
endometrial proliferation. However, in the LNG-IUS group 
15/18 women were amenorrheic, versus all women in the oral 
LNG group who continued with cyclic bleeding.49
Another study reviewed the available literature (19 studies 
with a total of 826 subjects) regarding progestin intrauterine 
devices in combination with estrogen, with a duration of 
six months to five years, and determined that none of the 
subjects developed endometrial hyperplasia throughout the 
course of the study.50
Hampton and colleagues evaluated 82 perimenopausal 
women treated with oral estrogen and the LNG-IUS for long 
term protection of the endometrium. Nonproliferative endo-
metrium was present in 98.6% of the participants at the end of 
12 months, 98.6% at 24 months, 95.5% at 36 months, 96.8% 
at 48 months, and 95.2% at 60 months. There were no cases of 
hyperplasia throughout the entire 60 month period. Amenorrhea 
was present in 54.4% of the women after 12 months, and 92.7% 
after 60 months. Overall the treatment was well tolerated, with 
79.8% of the women still continuing with the estrogen and 
LNG-IUS after the full 60 months of the study and 92.4% of the 
participants rating the treatment as “good” or “very good”.51
The LNG-IUS thus appears to be a highly effective and 
acceptable method of providing endometrial protection for 
peri- and postmenopausal women who are taking estrogen 
replacement therapy.
Patient acceptability of the LNG-IUS
The LNG-IUS is a safe and effective device which has been 
shown to be useful not only as a contraceptive, but as a tool 
which can be used for a variety of gynecologic conditions or 
disorders. However, the IUS is not without its side effects. 
The most common side effect associated with the LNG-IUS 
is menstrual irregularity. In fact, nearly 25% of women 
discontinue using the LNG-IUS because of amenorrhea.1 
Approximately 20% of LNG-IUS users will be amenor-
rheic by the end of 12 months,3 and 70% of users will be 
oligomenorrheic or amenorrheic by 24 months.52 In addition, 
though the systemic absorption is much smaller than with Therapeutics and Clinical Risk Management 2009:5 570
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other progestin-containing contraceptives, there is some 
absorption and it can occasionally be associated with a variety 
of undesirable side effects such as ovarian cysts, acne, weight 
gain, depression and decreased libido. However, the device 
seems to be well tolerated overall. A three-year study which 
specifically set out to evaluate the long-term acceptability of 
the LNG-IUS followed 165 women over 36 months. The study 
showed a three-year continuation rate of 90.3%. In total, 97% 
of participants reported alterations in their menstrual pattern, 
with 34% reporting a decrease in the amount of bleeding, 
17% had persistent spotting or intermenstrual bleeding, and 
56% reported at least a temporary period of amenorrhea. 
81% of the women with amenorrhea viewed it as a positive 
change for them. There was also a significant improvement 
in the amount of pain associated with menstruation, with a 
decrease from 60% to 29% in women reporting dysmenor-
rhea after 36 months. The number of women who expressed 
that they were very satisfied with the LNG-IUS increased 
steadily with the duration of the treatment, with 29% after 
two weeks, 56% after two months, 69% after six months and 
77% after 36 months.53
Another study of 78 women who had the LNG-IUS 
inserted for menstrual disorders also evaluated patient 
satisfaction through questionnaires. 12% of the women 
had the IUS prematurely removed, with the major reason 
being pain and heavy bleeding. However, the majority of 
participants were satisfied with their results. 78% of the 
women reported improvement in their periods, and 84% 
reported improvement in menstrual discomfort. 72% of the 
women reported they would use the LNG-IUS again, 73% 
would recommend it to their peers, and the overall satisfaction 
rate was 76%.54
The amount of satisfaction with the LNG-IUS, not 
surprisingly, appears to correlate with how well informed 
patients are about the possible side effects associated with it. 
A study that involved the evaluation of 17,914 questionnaires 
of current LNG-IUS users showed that 74% were very or 
fairly satisfied with it. User satisfaction correlated with 
the amount of information provided regarding different 
symptoms (menstrual irregularities, greasy hair/skin, 
pregnancy and PID) regardless of whether or not the patient 
actually experienced that specific symptom. In particular, the 
women who were warned of the possibility of amenorrhea 
were more satisfied than the women who were not.55
Conclusion
The levonorgestrel-releasing intrauterine system is a safe, 
effective and acceptable form of contraception being used by 
over 150 million women worldwide. It also has a multitude 
of noncontraceptive benefits including improvement 
in menorrhagia, decreased pelvic pain associated with 
endometriosis and adenomyosis, as well as a treatment for 
endometrial hyperplasia, an alternative to hysterectomy 
and an adjunct to estrogen replacement therapy. Overall 
the device is very well tolerated and patient satisfaction is 
quite high when the proper education regarding possible side 
effects has been provided. Despite all of the obvious benefits 
of the LNG-IUS, utilization rates remain quite low in the 
developed countries, and especially the United States. This 
is largely attributed to the negative history of the Dalkon 
Shield intrauterine device in the 1970s, which continues 
to negatively influence the opinions of both patients and 
health care providers. In addition, cost remains a barrier in 
less developed countries where demand might be high but 
the device is currently unaffordable in the public sector. 
Recently, with a concerted effort to train residents and 
providers in IUD and IUS use, a reversal of trends has been 
noted and the IUS is rapidly gaining market share in the 
US. This safe, acceptable and highly effective method will 
likely contribute significantly to the contraceptive method 
mix in the coming years.
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Appendix A Checklist for sexually transmitted infection (STi) risk assessment of intrauterine device (iUD) candidates8
Checklist for STI Risk Assessment of IUD Candidates
Name: Date:
Please circle the appropriate answers below: Yes No
1.
2.
3.
4.
5.
Is the client less than 25 years old?
Is she currently living apart from her husband or partner?
During the last year, has she had bleeding between periods or
bleeding or spotting within 24 hours after sex?
Is her school education less than secondary level?†
How many different sexual partners has she had during the last 3 months? Check A if none, B if
one, C if more than one.
If B or C, then ask her how often she used a condom when she had sex during the last 3 months
(never, some or always)?
1
1
0
0
0
0
0
0
0
0
1
1
1
1
1
A.
B.
C.
None
One
More than one
No condom use
No condom use
Some condom use
Some condom use
Always used condoms
Always used condoms
Add up the circled scores. Total Score:
Scoring
Recommended Action
Counsel/refer for an IUD insertion without
any reservations
Consider presumptive treatment for
chlamydia/gonorrhea (if available) or
counsel/refer to use another contraceptive
method
Low Cervical High Cervical
Infection Population Infection Population
(<10%) (=10%)
If score is 0−2
If score is 3+ If score is 1+
If score is 0
†The level may change from less than secondary level to a higher educational level if almost all women (>90%) have at
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Appendix B wHO risk categories for eligibility for use of an intrauterine device12
Risk category Description of category With clinical judgment Without clinical judgment
1 A condition for which there is 
no restriction for the use of 
the contraceptive method
Use the method in any 
circumstances
Use the method
2 A condition where the 
advantages of using the 
method generally outweigh 
the theoretical or proven risks
Generally use the method Use the method
3 A condition where the 
theoretical or proven 
risks usually outweigh the 
advantages of using the 
method
Use of the method not 
usually recommended unless 
other more appropriate 
methods are not available or 
not acceptable
Do not use the method
4 A condition which represents 
an unacceptable health risk 
if the contraceptive method 
is used
Method not to be used Do not use the method
Notes: “Clinical Judgement” means that a trained health care provider or the clinical resources to perform clinical tests and/or examinations are present.